Position;Phosphorylation site;Methylation site;Ubiquitination site;Caspase cleavage site;S-Nitrosylation site;Acetylation site;Sumoylation site;Residue part of a linear motif;WT residue;Mutated residue;Sources;Cancer study;Cancer type;Genomic coordinates;Genomic mutation;Revel score
1;-;-;-;-;-;-;-;;M
2;-;-;-;-;-;-;-;;P;L;COSMIC;-;carcinoma;hg38,chr1:241999004-241999004;hg38,chr1:241999004G>A;0.033
2;-;-;-;-;-;-;-;;P;S;cBioPortal,COSMIC;coad_tcga_pan_can_atlas_2018, coadread_tcga, coadread_tcga_pub;Colon Adenocarcinoma, Colorectal Adenocarcinoma, carcinoma;hg19,chr1:242162307-242162307, hg38,chr1:241999005-241999005;hg19,chr1:242162307G>A, hg38,chr1:241999005G>A;0.026
3;-;-;-;-;-;-;-;;P
4;-;-;-;-;-;-;-;;P;A;cBioPortal,COSMIC;luad_tcga, luad_tcga_pan_can_atlas_2018, luad_tcga_pub, nsclc_tcga_broad_2016;Lung Adenocarcinoma, Non-Small Cell Lung Cancer, carcinoma;hg19,chr1:242162301-242162301, hg38,chr1:241998999-241998999;hg19,chr1:242162301G>C, hg38,chr1:241998999G>C;0.035
5;-;-;-;-;-;-;-;;Q
6;-;-;-;-;-;-;-;;K
7;-;-;-;-;-;-;-;;I;F;COSMIC;-;chondrosarcoma;hg38,chr1:241998990-241998990;hg38,chr1:241998990T>A;0.020
8;-;-;-;-;-;-;-;;P;S;cBioPortal,COSMIC;cscc_hgsc_bcm_2014;Cutaneous Squamous Cell Carcinoma, carcinoma;hg19,chr1:242162289-242162289, hg38,chr1:241998987-241998987;hg19,chr1:242162289G>A, hg38,chr1:241998987G>A;0.056
9;-;-;-;-;-;-;-;;S
10;-;-;-;-;-;-;-;;V;I;cBioPortal;hnsc_tcga, hnsc_tcga_pan_can_atlas_2018, hnsc_tcga_pub;Head and Neck Squamous Cell Carcinoma;hg19,chr1:242162283-242162283;hg19,chr1:242162283C>T;0.029
11;-;-;-;-;-;-;-;MAPK docking motifs, 3, 11-21, ELM;R
12;-;-;-;-;-;-;-;MAPK docking motifs, 3, 11-21, ELM;P
13;-;-;-;-;-;-;-;MAPK docking motifs, 3, 11-21, ELM;F;L;cBioPortal;tgct_tcga;Tenosynovial Giant Cell Tumor Diffuse Type;hg19,chr1:242162272-242162272;hg19,chr1:242162272G>T;0.285
14;-;-;-;-;-;-;-;MAPK docking motifs, 3, 11-21, ELM|MAPK docking motifs, 4, 14-21, ELM;K
15;-;-;-;-;-;-;-;MAPK docking motifs, 3, 11-21, ELM|MAPK docking motifs, 4, 14-21, ELM;Q
16;-;-;-;-;-;-;-;MAPK docking motifs, 3, 11-21, ELM|MAPK docking motifs, 4, 14-21, ELM|14-3-3 binding phosphopeptide motif, 6, 16-20, ELM;R
17;-;-;-;-;-;-;-;MAPK docking motifs, 3, 11-21, ELM|MAPK docking motifs, 4, 14-21, ELM|14-3-3 binding phosphopeptide motif, 6, 16-20, ELM;K
18;-;-;-;-;-;-;-;MAPK docking motifs, 3, 11-21, ELM|MAPK docking motifs, 4, 14-21, ELM|14-3-3 binding phosphopeptide motif, 6, 16-20, ELM;S;C;cBioPortal,COSMIC;ov_tcga_pan_can_atlas_2018;carcinoma, ov;hg19,chr1:242162259-242162259, hg38,chr1:241998957-241998957;hg19,chr1:242162259T>A, hg38,chr1:241998957T>A;0.128
19;-;-;-;-;-;-;-;MAPK docking motifs, 3, 11-21, ELM|MAPK docking motifs, 4, 14-21, ELM|14-3-3 binding phosphopeptide motif, 6, 16-20, ELM;L
20;-;-;-;-;-;-;-;MAPK docking motifs, 3, 11-21, ELM|MAPK docking motifs, 4, 14-21, ELM|14-3-3 binding phosphopeptide motif, 6, 16-20, ELM;A
21;-;-;-;-;-;-;-;MAPK docking motifs, 3, 11-21, ELM|MAPK docking motifs, 4, 14-21, ELM;I;F;COSMIC;-;carcinoma;hg38,chr1:241998829-241998829;hg38,chr1:241998829T>A;0.041
22;-;-;-;-;-;-;-;;R
23;-;-;-;-;-;-;-;;Q
24;-;-;-;-;-;-;-;;E;D;COSMIC;-;carcinoma;hg38,chr1:241998818-241998818;hg38,chr1:241998818C>A;0.110
24;-;-;-;-;-;-;-;;E;Q;cBioPortal;brca_tcga_pan_can_atlas_2018;Invasive Breast Carcinoma;hg19,chr1:242162122-242162122;hg19,chr1:242162122C>G;0.042
25;-;-;-;-;-;-;-;;E
26;-;-;-;-;-;-;-;;V
27;-;-;-;-;-;-;-;;A
28;-;-;-;-;-;-;-;;G
29;-;-;-;-;-;-;-;MAPK docking motifs, 1, 29-41, ELM;I
30;-;-;-;-;-;-;-;MAPK docking motifs, 1, 29-41, ELM|MAPK docking motifs, 5, 30-39, ELM;R
31;-;-;-;-;-;-;-;MAPK docking motifs, 1, 29-41, ELM|MAPK docking motifs, 5, 30-39, ELM;A;V;cBioPortal;ucec_tcga_pan_can_atlas_2018;Endometrial Carcinoma;hg19,chr1:242162100-242162100;hg19,chr1:242162100G>A;0.092
32;-;-;-;-;-;-;-;MAPK docking motifs, 1, 29-41, ELM|MAPK docking motifs, 2, 32-41, ELM|MAPK docking motifs, 5, 30-39, ELM;K
33;-;-;-;-;-;-;-;MAPK docking motifs, 1, 29-41, ELM|MAPK docking motifs, 2, 32-41, ELM|MAPK docking motifs, 5, 30-39, ELM;F
34;-;-;-;-;-;-;-;MAPK docking motifs, 1, 29-41, ELM|MAPK docking motifs, 2, 32-41, ELM|MAPK docking motifs, 5, 30-39, ELM;P
35;-;-;-;-;-;-;-;MAPK docking motifs, 1, 29-41, ELM|MAPK docking motifs, 2, 32-41, ELM|MAPK docking motifs, 5, 30-39, ELM;N;S;cBioPortal;sarc_tcga_pan_can_atlas_2018;sarc;hg19,chr1:242162088-242162088;hg19,chr1:242162088T>C;0.073
36;-;-;-;-;-;-;-;MAPK docking motifs, 1, 29-41, ELM|MAPK docking motifs, 2, 32-41, ELM|MAPK docking motifs, 5, 30-39, ELM;K;T;cBioPortal,COSMIC;ucec_tcga, ucec_tcga_pan_can_atlas_2018, ucec_tcga_pub;Endometrial Carcinoma, carcinoma;hg19,chr1:242162085-242162085, hg38,chr1:241998783-241998783;hg19,chr1:242162085T>G, hg38,chr1:241998783T>G;0.433
37;-;-;-;-;-;-;-;MAPK docking motifs, 1, 29-41, ELM|MAPK docking motifs, 2, 32-41, ELM|MAPK docking motifs, 5, 30-39, ELM;I
38;-;-;-;-;-;-;-;MAPK docking motifs, 1, 29-41, ELM|MAPK docking motifs, 2, 32-41, ELM|MAPK docking motifs, 5, 30-39, ELM;P;L;cBioPortal,COSMIC;cscc_hgsc_bcm_2014;Cutaneous Squamous Cell Carcinoma, carcinoma;hg19,chr1:242162079-242162079, hg38,chr1:241998777-241998777;hg19,chr1:242162079G>A, hg38,chr1:241998777G>A;0.710
39;-;-;-;-;-;-;-;MAPK docking motifs, 1, 29-41, ELM|MAPK docking motifs, 2, 32-41, ELM|MAPK docking motifs, 5, 30-39, ELM;V
40;-;-;-;-;-;-;-;MAPK docking motifs, 1, 29-41, ELM|MAPK docking motifs, 2, 32-41, ELM;V
41;-;-;-;-;-;-;-;MAPK docking motifs, 1, 29-41, ELM|MAPK docking motifs, 2, 32-41, ELM;V
42;-;-;-;-;-;-;-;;E;V;cBioPortal;nepc_wcm_2016;nepc;hg19,chr1:242161912-242161912;hg19,chr1:242161912T>A;0.712
43;-;-;-;-;-;-;-;;R
44;-;-;-;-;-;-;-;;Y;C;cBioPortal,COSMIC;coad_tcga_pan_can_atlas_2018;Colon Adenocarcinoma, carcinoma;hg19,chr1:242161906-242161906, hg38,chr1:241998604-241998604;hg19,chr1:242161906T>C, hg38,chr1:241998604T>C;0.219
45;-;-;-;-;-;-;-;;P
46;-;-;-;-;-;-;-;;R;G;cBioPortal,COSMIC;coadread_genentech;Colorectal Adenocarcinoma, carcinoma;hg19,chr1:242161901-242161901, hg38,chr1:241998599-241998599;hg19,chr1:242161901T>C, hg38,chr1:241998599T>C;0.074
46;-;-;-;-;-;-;-;;R;M;COSMIC;-;carcinoma;hg38,chr1:241998598-241998598;hg38,chr1:241998598C>A;0.128
47;-;-;-;-;-;-;-;;E
48;-;-;-;-;-;-;-;;T
49;-;-;-;-;-;-;-;;F
50;-;-;-;-;-;-;-;;L
51;-;-;-;-;-;-;-;;P
52;-;-;-;-;-;-;-;;P;L;cBioPortal,COSMIC;lusc_tcga, lusc_tcga_pan_can_atlas_2018, lusc_tcga_pub, nsclc_tcga_broad_2016;Lung Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, carcinoma;hg19,chr1:242161882-242161882, hg38,chr1:241998580-241998580;hg19,chr1:242161882G>A, hg38,chr1:241998580G>A;0.049
52;-;-;-;-;-;-;-;;P;S;COSMIC;-;carcinoma;hg38,chr1:241998581-241998581;hg38,chr1:241998581G>A;0.047
53;-;-;-;-;-;-;-;;L
54;-;-;-;-;-;-;-;Cyclin docking motif, 0, 54-65, ELM;D;N;cBioPortal,COSMIC;skcm_broad_brafresist_2012;Cutaneous Melanoma, carcinoma, malignant_melanoma;hg19,chr1:242161877-242161877, hg38,chr1:241998575-241998575;hg19,chr1:242161877C>T, hg38,chr1:241998575C>T;0.270
55;-;-;-;-;-;-;-;Cyclin docking motif, 0, 54-65, ELM;K
56;-;-;-;-;-;-;-;Cyclin docking motif, 0, 54-65, ELM;T
57;-;-;-;-;-;-;-;Cyclin docking motif, 0, 54-65, ELM;K
58;-;-;-;-;-;-;-;Cyclin docking motif, 0, 54-65, ELM;F
59;-;-;-;-;-;-;-;Cyclin docking motif, 0, 54-65, ELM;L
60;-;-;-;-;-;-;-;Cyclin docking motif, 0, 54-65, ELM;V
61;-;-;-;-;-;-;-;Cyclin docking motif, 0, 54-65, ELM;P;S;COSMIC;-;carcinoma;hg38,chr1:241998554-241998554;hg38,chr1:241998554G>A;0.439
62;-;-;-;-;-;-;-;Cyclin docking motif, 0, 54-65, ELM;Q
63;-;-;-;-;-;-;-;Cyclin docking motif, 0, 54-65, ELM;E;V;cBioPortal,COSMIC;luad_broad;Lung Adenocarcinoma, carcinoma;hg19,chr1:242161849-242161849, hg38,chr1:241998547-241998547;hg19,chr1:242161849T>A, hg38,chr1:241998547T>A;0.199
64;-;-;-;-;-;-;-;Cyclin docking motif, 0, 54-65, ELM;L
65;-;-;-;-;-;-;-;Cyclin docking motif, 0, 54-65, ELM|Actin-binding motifs, 8, 65-82, ELM;T
66;-;-;-;-;-;-;-;Actin-binding motifs, 8, 65-82, ELM|Actin-binding motifs, 9, 66-82, ELM;M
67;-;-;-;-;-;-;-;Actin-binding motifs, 8, 65-82, ELM|Actin-binding motifs, 9, 66-82, ELM|Atg8 protein family ligands, 12, 67-72, ELM;T;I;cBioPortal,COSMIC;skcm_tcga, skcm_tcga_pan_can_atlas_2018;Cutaneous Melanoma, malignant_melanoma;hg19,chr1:242161837-242161837, hg38,chr1:241998535-241998535;hg19,chr1:242161837G>A, hg38,chr1:241998535G>A;0.100
68;-;-;-;-;-;-;-;Actin-binding motifs, 8, 65-82, ELM|Actin-binding motifs, 9, 66-82, ELM|Atg8 protein family ligands, 12, 67-72, ELM|NES Nuclear Export Signal, 23, 68-83, ELM;Q
69;-;-;-;-;-;-;-;Actin-binding motifs, 8, 65-82, ELM|Actin-binding motifs, 9, 66-82, ELM|Atg8 protein family ligands, 12, 67-72, ELM|NES Nuclear Export Signal, 23, 68-83, ELM;F
70;-;-;-;-;-;-;-;Actin-binding motifs, 8, 65-82, ELM|Actin-binding motifs, 9, 66-82, ELM|Atg8 protein family ligands, 12, 67-72, ELM|NES Nuclear Export Signal, 23, 68-83, ELM;L
71;-;-;-;-;-;-;-;Actin-binding motifs, 8, 65-82, ELM|Actin-binding motifs, 9, 66-82, ELM|Atg8 protein family ligands, 12, 67-72, ELM|NES Nuclear Export Signal, 23, 68-83, ELM;S;G;cBioPortal,COSMIC;ucec_tcga, ucec_tcga_pan_can_atlas_2018, ucec_tcga_pub;Endometrial Carcinoma, carcinoma;hg19,chr1:242161826-242161826, hg38,chr1:241998524-241998524;hg19,chr1:242161826T>C, hg38,chr1:241998524T>C;0.128
72;-;-;-;-;-;-;-;Actin-binding motifs, 8, 65-82, ELM|Actin-binding motifs, 9, 66-82, ELM|Atg8 protein family ligands, 12, 67-72, ELM|NES Nuclear Export Signal, 23, 68-83, ELM;I
73;-;-;-;-;-;-;-;Actin-binding motifs, 8, 65-82, ELM|Actin-binding motifs, 9, 66-82, ELM|di Arginine retention/retrieving signal, 20, 73-76, ELM|NES Nuclear Export Signal, 23, 68-83, ELM;I
74;-;-;-;-;-;-;-;Actin-binding motifs, 8, 65-82, ELM|Actin-binding motifs, 9, 66-82, ELM|di Arginine retention/retrieving signal, 20, 73-76, ELM|di Arginine retention/retrieving signal, 21, 74-77, ELM|NES Nuclear Export Signal, 23, 68-83, ELM;R;L;cBioPortal;skcm_tcga_pan_can_atlas_2018;Cutaneous Melanoma;hg19,chr1:242161816-242161816;hg19,chr1:242161816C>A;0.403
75;-;-;-;-;-;-;-;Actin-binding motifs, 8, 65-82, ELM|Actin-binding motifs, 9, 66-82, ELM|di Arginine retention/retrieving signal, 20, 73-76, ELM|di Arginine retention/retrieving signal, 21, 74-77, ELM|NES Nuclear Export Signal, 23, 68-83, ELM;S
76;-;-;-;-;-;-;-;Actin-binding motifs, 8, 65-82, ELM|Actin-binding motifs, 9, 66-82, ELM|di Arginine retention/retrieving signal, 20, 73-76, ELM|di Arginine retention/retrieving signal, 21, 74-77, ELM|NES Nuclear Export Signal, 23, 68-83, ELM;R;C;cBioPortal,COSMIC;coad_tcga_pan_can_atlas_2018, coadread_dfci_2016, esca_tcga_pan_can_atlas_2018, ucec_tcga, ucec_tcga_pan_can_atlas_2018, ucec_tcga_pub;Colon Adenocarcinoma, Colorectal Adenocarcinoma, Endometrial Carcinoma, Esophageal Adenocarcinoma, carcinoma;hg19,chr1:242159683-242159683, hg38,chr1:241996381-241996381;hg19,chr1:242159683G>A, hg38,chr1:241996381G>A;0.316
76;-;-;-;-;-;-;-;Actin-binding motifs, 8, 65-82, ELM|Actin-binding motifs, 9, 66-82, ELM|di Arginine retention/retrieving signal, 20, 73-76, ELM|di Arginine retention/retrieving signal, 21, 74-77, ELM|NES Nuclear Export Signal, 23, 68-83, ELM;R;H;cBioPortal,COSMIC;mixed_allen_2018, skcm_broad;Cutaneous Melanoma, Mixed Cancer Types, carcinoma;hg19,chr1:242159682-242159682, hg38,chr1:241996380-241996380;hg19,chr1:242159682C>T, hg38,chr1:241996380C>T;0.330
76;-;-;-;-;-;-;-;Actin-binding motifs, 8, 65-82, ELM|Actin-binding motifs, 9, 66-82, ELM|di Arginine retention/retrieving signal, 20, 73-76, ELM|di Arginine retention/retrieving signal, 21, 74-77, ELM|NES Nuclear Export Signal, 23, 68-83, ELM;R;L;cBioPortal;luad_tcga_pan_can_atlas_2018, nsclc_tcga_broad_2016;Lung Adenocarcinoma, Non-Small Cell Lung Cancer;hg19,chr1:242159682-242159682;hg19,chr1:242159682C>A;0.410
77;-;-;-;-;-;-;-;Actin-binding motifs, 8, 65-82, ELM|Actin-binding motifs, 9, 66-82, ELM|di Arginine retention/retrieving signal, 21, 74-77, ELM|NES Nuclear Export Signal, 23, 68-83, ELM;M;I;cBioPortal;mixed_allen_2018;Mixed Cancer Types;hg19,chr1:242159678-242159678;hg19,chr1:242159678C>T;0.092
78;-;-;-;-;-;-;-;Actin-binding motifs, 8, 65-82, ELM|Actin-binding motifs, 9, 66-82, ELM|NES Nuclear Export Signal, 23, 68-83, ELM;V
79;-;-;-;-;-;-;-;Actin-binding motifs, 8, 65-82, ELM|Actin-binding motifs, 9, 66-82, ELM|NES Nuclear Export Signal, 23, 68-83, ELM;L
80;-;-;-;-;-;-;-;14-3-3 binding phosphopeptide motif, 7, 80-88, ELM|Actin-binding motifs, 8, 65-82, ELM|Actin-binding motifs, 9, 66-82, ELM|NES Nuclear Export Signal, 23, 68-83, ELM;R
81;-;-;-;-;-;-;-;14-3-3 binding phosphopeptide motif, 7, 80-88, ELM|Actin-binding motifs, 8, 65-82, ELM|Actin-binding motifs, 9, 66-82, ELM|NES Nuclear Export Signal, 23, 68-83, ELM;A;T;cBioPortal,COSMIC;ov_tcga, ov_tcga_pan_can_atlas_2018, ov_tcga_pub;carcinoma, ov;hg19,chr1:242159668-242159668, hg38,chr1:241996366-241996366;hg19,chr1:242159668C>T, hg38,chr1:241996366C>T;0.144
81;-;-;-;-;-;-;-;14-3-3 binding phosphopeptide motif, 7, 80-88, ELM|Actin-binding motifs, 8, 65-82, ELM|Actin-binding motifs, 9, 66-82, ELM|NES Nuclear Export Signal, 23, 68-83, ELM;A;V;cBioPortal;ucec_tcga_pan_can_atlas_2018;Endometrial Carcinoma;hg19,chr1:242159667-242159667;hg19,chr1:242159667G>A;0.201
82;-;-;-;-;-;-;-;14-3-3 binding phosphopeptide motif, 7, 80-88, ELM|Actin-binding motifs, 8, 65-82, ELM|Actin-binding motifs, 9, 66-82, ELM|Atg8 protein family ligands, 13, 82-88, ELM|NES Nuclear Export Signal, 23, 68-83, ELM;T;M;cBioPortal,COSMIC;ucec_tcga, ucec_tcga_pan_can_atlas_2018, ucec_tcga_pub;Endometrial Carcinoma, carcinoma;hg19,chr1:242159664-242159664, hg38,chr1:241996362-241996362;hg19,chr1:242159664G>A, hg38,chr1:241996362G>A;0.140
83;-;-;-;-;-;-;-;14-3-3 binding phosphopeptide motif, 7, 80-88, ELM|Atg8 protein family ligands, 13, 82-88, ELM|Atg8 protein family ligands, 14, 83-89, ELM|Endosome-Lysosome-Basolateral sorting signals, 22, 83-88, ELM|NES Nuclear Export Signal, 23, 68-83, ELM;E
84;-;-;-;-;-;-;-;14-3-3 binding phosphopeptide motif, 7, 80-88, ELM|Atg8 protein family ligands, 13, 82-88, ELM|Atg8 protein family ligands, 14, 83-89, ELM|Endosome-Lysosome-Basolateral sorting signals, 22, 83-88, ELM;A;T;cBioPortal;paad_tcga, paad_tcga_pan_can_atlas_2018;Pancreatic Adenocarcinoma;hg19,chr1:242159659-242159659;hg19,chr1:242159659C>T;0.317
85;-;-;-;-;-;-;-;14-3-3 binding phosphopeptide motif, 7, 80-88, ELM|Atg8 protein family ligands, 13, 82-88, ELM|Atg8 protein family ligands, 14, 83-89, ELM|Endosome-Lysosome-Basolateral sorting signals, 22, 83-88, ELM;F;L;cBioPortal;ampca_bcm_2016;Ampullary Carcinoma;hg19,chr1:242159656-242159656;hg19,chr1:242159656A>G;0.213
86;-;-;-;-;-;-;-;14-3-3 binding phosphopeptide motif, 7, 80-88, ELM|Atg8 protein family ligands, 13, 82-88, ELM|Atg8 protein family ligands, 14, 83-89, ELM|SH2 ligand, 16, 86-89, ELM|Y-based sorting signal, 19, 86-89, ELM|Endosome-Lysosome-Basolateral sorting signals, 22, 83-88, ELM;Y
87;-;-;-;-;-;-;-;14-3-3 binding phosphopeptide motif, 7, 80-88, ELM|Atg8 protein family ligands, 13, 82-88, ELM|Atg8 protein family ligands, 14, 83-89, ELM|SH2 ligand, 16, 86-89, ELM|Y-based sorting signal, 19, 86-89, ELM|Endosome-Lysosome-Basolateral sorting signals, 22, 83-88, ELM;L
88;-;-;-;-;-;-;-;14-3-3 binding phosphopeptide motif, 7, 80-88, ELM|Atg8 protein family ligands, 13, 82-88, ELM|Atg8 protein family ligands, 14, 83-89, ELM|SH2 ligand, 16, 86-89, ELM|Y-based sorting signal, 19, 86-89, ELM|Endosome-Lysosome-Basolateral sorting signals, 22, 83-88, ELM;L
89;-;-;-;-;-;-;-;Atg8 protein family ligands, 14, 83-89, ELM|SH2 ligand, 16, 86-89, ELM|Y-based sorting signal, 19, 86-89, ELM;V
90;-;-;-;-;-;-;-;;N
91;-;-;-;-;-;-;-;;N
92;-;-;-;-;-;-;-;;K
93;-;-;-;-;-;-;-;;S
94;-;-;-;-;-;-;-;;L
95;-;-;-;-;-;-;-;;V;D;COSMIC;-;carcinoma;hg38,chr1:241996323-241996323;hg38,chr1:241996323A>T;0.223
96;-;-;-;-;-;-;-;;S;T;COSMIC;-;carcinoma;hg38,chr1:241996320-241996320;hg38,chr1:241996320C>G;0.229
97;-;-;-;-;-;-;-;;M;I;cBioPortal;hnsc_tcga, hnsc_tcga_pan_can_atlas_2018;Head and Neck Squamous Cell Carcinoma;hg19,chr1:242159618-242159618;hg19,chr1:242159618C>T;0.149
98;-;-;-;-;-;-;-;;S;R;COSMIC;-;carcinoma;hg38,chr1:241996313-241996313;hg38,chr1:241996313G>T;0.194
99;-;-;-;-;-;-;-;;A
100;-;-;-;-;-;-;-;;T;S;cBioPortal,COSMIC;brca_tcga, brca_tcga_pan_can_atlas_2018, brca_tcga_pub, brca_tcga_pub2015;Invasive Breast Carcinoma, carcinoma;hg19,chr1:242159611-242159611, hg38,chr1:241996309-241996309;hg19,chr1:242159611T>A, hg38,chr1:241996309T>A;0.182
101;-;-;-;-;-;-;-;;M;I;COSMIC;-;carcinoma;hg38,chr1:241996304-241996304;hg38,chr1:241996304C>A;0.120
102;-;-;-;-;-;-;-;;A;T;cBioPortal,COSMIC;coad_tcga_pan_can_atlas_2018;Colon Adenocarcinoma, carcinoma;hg19,chr1:242159605-242159605, hg38,chr1:241996303-241996303;hg19,chr1:242159605C>T, hg38,chr1:241996303C>T;0.107
103;-;-;-;-;-;-;-;;E;K;COSMIC;-;germ_cell_tumour;hg38,chr1:241996300-241996300;hg38,chr1:241996300C>T;0.243
104;-;-;-;-;-;-;-;;I
105;-;-;-;-;-;-;-;;Y;C;COSMIC;-;carcinoma;hg38,chr1:241996293-241996293;hg38,chr1:241996293T>C;0.669
106;-;-;-;-;-;-;-;;R
107;-;-;-;-;-;-;-;;D;N;cBioPortal,COSMIC;skcm_tcga_pan_can_atlas_2018, skcm_yale;Cutaneous Melanoma, malignant_melanoma;hg19,chr1:242159590-242159590, hg38,chr1:241996288-241996288;hg19,chr1:242159590C>T, hg38,chr1:241996288C>T;0.133
108;-;-;-;-;-;-;-;;Y;H;cBioPortal,COSMIC;prad_broad, prad_p1000;Prostate Adenocarcinoma, carcinoma;hg19,chr1:242159587-242159587, hg38,chr1:241996285-241996285;hg19,chr1:242159587A>G, hg38,chr1:241996285A>G;0.052
109;-;-;-;-;-;-;-;;K
110;-;-;-;-;-;-;-;;D
111;-;-;-;-;-;-;-;;E;K;cBioPortal;blca_tcga_pan_can_atlas_2018, blca_tcga_pub_2017;Bladder Urothelial Carcinoma;hg19,chr1:242159578-242159578;hg19,chr1:242159578C>T;0.080
112;-;-;-;-;-;-;-;;D;H;cBioPortal;lihc_amc_prv;lihc;hg19,chr1:242159575-242159575;hg19,chr1:242159575C>G;0.637
113;-;-;-;-;-;-;-;;G;V;cBioPortal;prad_p1000, prad_tcga, prad_tcga_pan_can_atlas_2018;Prostate Adenocarcinoma;hg19,chr1:242159571-242159571;hg19,chr1:242159571C>A;0.533
114;-;-;-;-;-;-;-;;F
115;-;-;-;-;-;-;-;;V;L;cBioPortal;ov_tcga_pan_can_atlas_2018;ov;hg19,chr1:242159566-242159566;hg19,chr1:242159566C>A;0.053
115;-;-;-;-;-;-;-;;V;M;cBioPortal,COSMIC;stad_tcga, stad_tcga_pan_can_atlas_2018, stad_tcga_pub, stes_tcga_pub;Stomach Adenocarcinoma, carcinoma, stes;hg19,chr1:242159566-242159566, hg38,chr1:241996264-241996264;hg19,chr1:242159566C>T, hg38,chr1:241996264C>T;0.090
116;-;-;-;-;-;-;-;;Y
117;-;-;-;-;-;-;-;;M;I;cBioPortal,COSMIC;coadread_dfci_2016, skcm_tcga, skcm_tcga_pan_can_atlas_2018;Colorectal Adenocarcinoma, Cutaneous Melanoma, carcinoma, malignant_melanoma;hg19,chr1:242159558-242159558, hg38,chr1:241996256-241996256;hg19,chr1:242159558C>T, hg38,chr1:241996256C>T;0.139
117;-;-;-;-;-;-;-;;M;L;cBioPortal;skcm_broad;Cutaneous Melanoma;hg19,chr1:242159560-242159560;hg19,chr1:242159560T>A;0.172
118;-;-;-;-;-;-;-;;T
119;-;-;-;-;-;-;-;SH2 ligand, 15, 119-122, ELM;Y;S;cBioPortal;luad_broad, nsclc_tcga_broad_2016;Lung Adenocarcinoma, Non-Small Cell Lung Cancer;hg19,chr1:242159553-242159553;hg19,chr1:242159553T>G;0.435
120;-;-;-;-;-;-;-;SH2 ligand, 15, 119-122, ELM|TRAF2 binding site, 18, 120-123, ELM;A;T;cBioPortal,COSMIC;prad_p1000;Prostate Adenocarcinoma, carcinoma;hg19,chr1:242159551-242159551, hg38,chr1:241996249-241996249;hg19,chr1:242159551C>T, hg38,chr1:241996249C>T;0.126
121;-;-;-;-;-;-;-;SH2 ligand, 15, 119-122, ELM|TRAF2 binding site, 18, 120-123, ELM;S;C;cBioPortal;lusc_tcga_pan_can_atlas_2018, nsclc_tcga_broad_2016;Lung Squamous Cell Carcinoma, Non-Small Cell Lung Cancer;hg19,chr1:242159547-242159547;hg19,chr1:242159547G>C;0.449
121;-;-;-;-;-;-;-;SH2 ligand, 15, 119-122, ELM|TRAF2 binding site, 18, 120-123, ELM;S;F;COSMIC;-;malignant_melanoma;hg38,chr1:241996245-241996245;hg38,chr1:241996245G>A;0.599
122;-;-;-;-;-;-;-;SH2 ligand, 15, 119-122, ELM|TRAF2 binding site, 18, 120-123, ELM;Q;K;COSMIC;-;other;hg38,chr1:241996243-241996243;hg38,chr1:241996243G>T;0.448
123;-;-;-;-;-;-;-;Atg8 protein family ligands, 10, 123-128, ELM|TRAF2 binding site, 18, 120-123, ELM;E;D;cBioPortal;prad_p1000, prad_tcga, prad_tcga_pan_can_atlas_2018;Prostate Adenocarcinoma;hg19,chr1:242159540-242159540;hg19,chr1:242159540C>A;0.117
123;-;-;-;-;-;-;-;Atg8 protein family ligands, 10, 123-128, ELM|TRAF2 binding site, 18, 120-123, ELM;E;K;COSMIC;-;carcinoma;hg38,chr1:241996240-241996240;hg38,chr1:241996240C>T;0.185
124;-;-;-;-;-;-;-;Atg8 protein family ligands, 10, 123-128, ELM|Atg8 protein family ligands, 11, 124-128, ELM;T;I;cBioPortal;luad_tcga_pan_can_atlas_2018;Lung Adenocarcinoma;hg19,chr1:242159538-242159538;hg19,chr1:242159538G>A;0.143
125;-;-;-;-;-;-;-;Atg8 protein family ligands, 10, 123-128, ELM|Atg8 protein family ligands, 11, 124-128, ELM;F
126;-;-;-;-;-;-;-;Atg8 protein family ligands, 10, 123-128, ELM|Atg8 protein family ligands, 11, 124-128, ELM;G
127;-;-;-;-;-;-;-;Atg8 protein family ligands, 10, 123-128, ELM|Atg8 protein family ligands, 11, 124-128, ELM;C
128;-;-;-;-;-;-;-;Atg8 protein family ligands, 10, 123-128, ELM|Atg8 protein family ligands, 11, 124-128, ELM;L
129;-;-;-;-;-;-;-;;E
130;-;-;-;-;-;-;-;;S;L;cBioPortal,COSMIC;nccrcc_genentech_2014;Renal Non-Clear Cell Carcinoma, carcinoma;hg19,chr1:242159520-242159520, hg38,chr1:241996218-241996218;hg19,chr1:242159520G>A, hg38,chr1:241996218G>A;0.004
130;-;-;-;-;-;-;-;;S;T;cBioPortal,COSMIC;nccrcc_genentech_2014;Renal Non-Clear Cell Carcinoma, carcinoma;hg19,chr1:242159521-242159521, hg38,chr1:241996219-241996219;hg19,chr1:242159521A>T, hg38,chr1:241996219A>T;0.007
131;-;-;-;-;-;-;-;;A
132;-;-;-;-;-;-;-;;A;D;cBioPortal,COSMIC;cscc_hgsc_bcm_2014;Cutaneous Squamous Cell Carcinoma, carcinoma;hg19,chr1:242159514-242159514, hg38,chr1:241996212-241996212;hg19,chr1:242159514G>T, hg38,chr1:241996212G>T;0.169
133;-;-;-;-;-;-;-;;P
134;-;-;-;-;-;-;-;;R;W;cBioPortal,COSMIC;lusc_tcga, lusc_tcga_pan_can_atlas_2018, lusc_tcga_pub, nsclc_tcga_broad_2016;Lung Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, carcinoma;hg19,chr1:242159509-242159509, hg38,chr1:241996207-241996207;hg19,chr1:242159509T>A, hg38,chr1:241996207T>A;0.030
135;-;-;-;-;-;-;-;;D
136;-;-;-;-;-;-;-;;G
137;-;-;-;-;-;-;-;;S
138;-;-;-;-;-;-;-;;S
139;-;-;-;-;-;-;-;;L
140;-;-;-;-;-;-;-;SH3 ligand, 17, 140-146, ELM;E
141;-;-;-;-;-;-;-;SH3 ligand, 17, 140-146, ELM;D;E;cBioPortal;luad_tcga_pan_can_atlas_2018, nsclc_tcga_broad_2016;Lung Adenocarcinoma, Non-Small Cell Lung Cancer;hg19,chr1:242159486-242159486;hg19,chr1:242159486G>T;0.045
142;-;-;-;-;-;-;-;SH3 ligand, 17, 140-146, ELM;R
143;-;-;-;-;-;-;-;SH3 ligand, 17, 140-146, ELM;P;H;cBioPortal;thym_tcga_pan_can_atlas_2018;Thymoma;hg19,chr1:242159481-242159481;hg19,chr1:242159481G>T;0.081
144;-;-;-;-;-;-;-;SH3 ligand, 17, 140-146, ELM;C
145;-;-;-;-;-;-;-;SH3 ligand, 17, 140-146, ELM;N
146;-;-;-;-;-;-;-;SH3 ligand, 17, 140-146, ELM;P;L;cBioPortal,COSMIC;cscc_hgsc_bcm_2014;Cutaneous Squamous Cell Carcinoma, carcinoma;hg19,chr1:242159472-242159472, hg38,chr1:241996170-241996170;hg19,chr1:242159472G>A, hg38,chr1:241996170G>A;0.022
146;-;-;-;-;-;-;-;SH3 ligand, 17, 140-146, ELM;P;T;COSMIC;-;carcinoma;hg38,chr1:241996171-241996171;hg38,chr1:241996171G>T;0.028
147;-;-;-;-;-;-;-;;L
